ABSTRACT
The potential role of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition in the management of COVID-19 and other medical conditions has emerged as an intriguing area of research. PCSK9 is primarily known for its impact on cholesterol metabolism, but recent studies have unveiled its involvement in various physiological processes, including inflammation, immune regulation, and thrombosis. In this abstract, the authors review the rationale and potential implications of PCSK9 inhibition during the inflammatory stage of SARS-CoV-2 infection. Severe cases of COVID-19 are characterized by an uncontrolled inflammatory response, often referred to as the cytokine storm, which can lead to widespread tissue damage and organ failure. Preclinical studies suggest that PCSK9 inhibition could dampen this inflammatory cascade by reducing the production of pro-inflammatory cytokines. Additionally, PCSK9 inhibition may protect against acute respiratory distress syndrome (ARDS) through its effects on lung injury and inflammation. COVID-19 has been linked to an increased risk of cardiovascular complications, especially in patients with pre-existing cardiovascular conditions or dyslipidemia. PCSK9 inhibitors are known for their ability to lower low-density lipoprotein (LDL) cholesterol levels by enhancing the recycling of LDL receptors in the liver. By reducing LDL cholesterol, PCSK9 inhibition might protect blood vessels from further damage and lower the risk of atherosclerotic plaque formation. Moreover, PCSK9 inhibitors have shown potential antithrombotic effects in preclinical studies, making them a potential avenue to mitigate the increased risk of coagulation disorders and thrombotic events observed in COVID-19. While the potential implications of PCSK9 inhibition are promising, safety considerations and possible risks need careful evaluation. Hypocholesterolemia, drug interactions, and long-term safety are some of the key concerns that should be addressed. Clinical trials are needed to establish the efficacy and safety of PCSK9 inhibitors in COVID-19 patients and to determine the optimal timing and dosing for treatment. Future research opportunities encompass investigating the immune response, evaluating long-term safety, exploring combination therapy possibilities, and advancing personalized medicine approaches. Collaborative efforts from researchers, clinicians, and policymakers are essential to fully harness the therapeutic potential of PCSK9 inhibition and translate these findings into meaningful clinical outcomes.
ABSTRACT
INTRODUCTION: Utilized in the healthcare sector, social media offers numerous benefits. However, its drawbacks encompass the variable quality of unregulated and unsupervised content. Thus, we aimed to evaluate the information in content related to chest pain found across Instagram and analyze the quality and reliability of chest pain-related content via Instagram posts. METHODOLOGY: Instagram posts with content related to chest pain were analyzed with the help of a structured questionnaire that included the Global Quality Scale (GQS) and DISCERN score (DS). To collect Instagram posts, several distinct hashtags were employed: #chestpain, #chestpains, #angina, #anginatreatment, #heartattack, #heartattacksurvivor, #heartattackprevention. RESULTS: A total of 262 posts were included, of which 29.7% of the total posts (n=78) contained information that describes the etiology of the disease. 27.8% of the total posts (n = 73) enclosed promotional content. Posts were found to be uploaded by doctors (18.7%), hospitals (15.6%), patients (17.9%), dieticians (11.1%), healthcare organizations (9.2%), and others (27.5%). Both Global Quality and DISCERN scores were statistically significant with a p-value of 0.001. CONCLUSIONS: The findings of this study revealed that most of the Instagram content on chest pain posted via physicians were highly reliable and had a better global quality score. Information regarding various causes, symptoms and preventive measures on Instagram can be considered as an acceptable source for patients to surf on. A major limitation is that only English content was analyzed. In the future, the use of higher quality posts produced by healthcare professionals could potentially contribute to enhancing patient education via Instagram.
ABSTRACT
This review provides an updated overview of the efficacy and safety of pitavastatin in patients with impaired glucose tolerance (IGT). IGT is a prediabetic state characterized by elevated blood glucose levels that do not meet the criteria for diabetes. The review explores the potential benefits of pitavastatin in reducing cardiovascular risk and improving lipid profiles in individuals with IGT. It also examines the glycemic effects of pitavastatin, including its impact on fasting blood glucose levels, insulin sensitivity, and beta-cell function. The review highlights the need for individualized treatment approaches, taking into account the patient's overall cardiovascular risk profile and glycemic control needs. While pitavastatin has shown modest improvements in glycemic control, it is not a substitute for lifestyle modifications or standard antidiabetic medications. Future directions for research include long-term follow-up studies, mechanistic investigations, and comparative analyses to further understand the glycemic effects of pitavastatin in IGT. Overall, this narrative review provides valuable insights for healthcare professionals involved in the management of individuals with IGT, emphasizing the importance of a comprehensive approach to reduce cardiovascular risk and optimize glycemic control.
